ATLANTA, GA – – (Newsfile Corp. – September 25, 2020) – – Holzer & Holzer, LLC announces that a class action lawsuit has been filed on behalf of investors who purchased Odonate Therapeutics, Inc. (“Odonate” or the “Company”) (NASDAQ: ODT) securities between December 7, 2017 and August 21, 2020 (the “Class Period”). Investors who purchased the Company’s securities during the Class Period and are interested in serving as lead plaintiff are encouraged to contact the firm before the November 16, 2020 deadline. The complaint alleges throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) tesetaxel was not as safe or well-tolerated as the Company had led investors to believe; (ii) consequently, tesetaxel’s commercial viability as a cancer treatment was overstated; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. If you purchased shares of Odonate securities between December 7, 2017 and August 21, 2020 and suffered significant losses on that investment, you are encouraged to contact Corey D. Holzer, Esq. at email@example.com or Luke R. Kennedy, Esq. at firstname.lastname@example.org, or through www.holzerlaw.com to discuss your legal rights.